CALT - Calliditas Therapeutics AB (publ)
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 17.84 |
| Open | 17.25 |
| Bid | 17.08 x 1000 |
| Ask | 17.56 x 800 |
| Day's Range | 16.88 - 17.55 |
| 52 Week Range | 10.82 - 25.64 |
| Volume | |
| Avg. Volume | 11,316 |
| Market Cap | 461.037M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.42 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.00 |
Fair Value
Related Research
PR NewswireBulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 30 May 2023, in Stockholm.
PR NewswireCalliditas Therapeutics: Interim Report Q1, 2023
Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout
PR NewswireCalliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
PR NewswireNotice of annual general meeting of Calliditas Therapeutics AB (publ)
The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on Tuesday 30 May 2023 at Klara, Klarabergsviadukten 90, Stockholm, Sweden. Registration starts at 10.00 CEST.
PR NewswireCalliditas Therapeutics' 2022 Annual Report Published
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2022 now is available at the company's website: www.calliditas.com
GlobeNewswireCalliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) versus standard of care (SOC) for people with Primary IgA Nephropathy (IgAN) in the United States (US). The analysis was published in the peer-reviewed journal ClinicoEconomics and Outcomes Research. Researchers used a healt
PR NewswireCalliditas to participate in upcoming investor conferences
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following investor conferences:
Motley Fool3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
The main stock indexes are way down over the past year, but quite a few under-the-radar stocks have bucked the trend. Reata Pharmaceuticals (NASDAQ: RETA) was a clinical-stage biopharmaceutical company until the U.S. Food and Drug Administration (FDA) approved its first treatment on Feb. 28, 2023. Reata's first approved product, Skyclarys, is the first and only drug approved to treat Friedreich's ataxia, an ultra-rare neuromuscular disease.
BenzingaCalliditas Plans To File For Complete FDA Approval For Rare Kidney Disease Drug After Positive Phase 3 Data
Calliditas Therapeutics AB (NASDAQ: CALT) announced topline results from the Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO/Kinpeygo (budesonide) delayed-release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). The trial studied Nefecon on primary IgA nephropathy (IgAN) patients who were also on RAS inhibitor therapy. The drug demonstrated a "highly statistically significant benefit" over the placebo in two years, with nine months of t
PR NewswireCalliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy
Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN).
BenzingaAnalyst Sits On Fence While Initiating Calliditas Citing 'Near-Term Opportunity But Longer-Term Questions'
Guggenheim initiated coverage on Calliditas Therapeutics AB (NASDAQ: CALT) with a Neutral rating and an $18 price target. The analyst is impressed with the data Tarpeyo has generated in Immunoglobulin A Nephropathy (IgAN) to date and the initial success the company has had with the commercial rollout of the product. While the analyst commends the Calliditas team for their progress with Tarpeyo in IgAN, including obtaining FDA Accelerated Approval and EU Conditional Approval, it notes mixed physi
PR NewswireCalliditas - Year-End Report, 2022
"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA nephropathy and a medication with the potential to be disease modifying based on the early stabilization of eGFR in patients at risk of rapid disease progression. We achieved total revenues of SEK 802.9 million ($79.3m) for the year of 2022, which represent an increase of 250% compared to 2021, whereof SEK 372.2 million ($36.8m) was net sales of TARPEYO for the first 11 months of commerci
PR NewswireCalliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.
PR NewswireNumber of shares and votes in Calliditas Therapeutics
During January, Calliditas Therapeutics AB (publ) has issued 7,500 common shares connected to the company's long term incentive program 2019/2022. Thus, as of January 31, 2023, the number of shares and votes in the company amounts to 59,580,087 shares and 59,580,087 votes.
ZacksNew Strong Sell Stocks for January 6th
CALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023.
PR NewswireChina CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for the New Drug Application (NDA) of Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression.
PR NewswireCalliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022
Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net purchased 50,000 shares through Calliditas' warrant program 2019/2022. Following the new subscription for shares, her shareholding in the company will amount to 643,000 common shares.
PR NewswireCalliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") announced today that they have entered into an exclusive license agreement with Viatris Pharmaceuticals Japan Inc., a subsidiary of Viatris Inc. (NASDAQ: VTRS) ("Viatris"), to register and commercialize Nefecon, a specialty drug recently approved in Europe and the US for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in Japan.
PR NewswireCalliditas to host fireside chat with its China commercial partner, Everest Medicines
Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial partner Everest Medicines (HKEX 1952.HK, "Everest") on Wednesday, December 14th, 2022 at 8am Eastern Time (2pm Central European Time, 8pm China Standard Time).
PR NewswireCalliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Products Administration ("NMPA") has accepted Everest Medicines' (HKEX 1952.HK, "Everest") New Drug Application ("NDA") for Nefecon. The acceptance brings Nefecon, approved and marketed in the U.S. under the name TARPEYO® and in the E.U. as Kinpeygo®, an important step closer to potentially becoming the first-ever approved therapeutic option in
PR NewswireCalliditas Therapeutics: Interim Report Q3, 2022
"On July 15th the European Commission issued the conditional marketing authorization for Kinpeygo, which marked the first time that any drug has achieved approval for this rare disease in EU. We immediately started the process of transferring the market authorization to our European partner, STADA Arzneimittel AG, in order to enable a launch in Europe as quickly as possible. STADA is initially launching the product in Germany, with other European countries to follow over time.
PR NewswireKey Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape
Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Fireside Chat on the IgA Nephropathy (IgAN) treatment landscape in the US on Tuesday, November 8th, 2022 at 1:30pm Eastern Time.
ZacksAurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PR NewswireCalliditas Therapeutics' nomination committee composition for the AGM 2023
The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting in 2017, consists of:
PR NewswireKidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the successful results from NefIgArd Part A, their pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter study.